Although this association has not (yet) been validated with immunotherapy or targeted agents, in recent years, DFS was frequently applied as the primary endpoint in randomized trials involving EGFR-mutated resected NSCLC treated with EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.